Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Water and sodium in heart failure: a spotlight on congestion.

Parrinello G, Greene SJ, Torres D, Alderman M, Bonventre JV, Di Pasquale P, Gargani L, Nohria A, Fonarow GC, Vaduganathan M, Butler J, Paterna S, Stevenson LW, Gheorghiade M.

Heart Fail Rev. 2015 Jan;20(1):13-24. doi: 10.1007/s10741-014-9438-7. Review.

2.

Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function, and prognosis.

Costanzo MR, Jessup M.

Heart Fail Rev. 2012 Mar;17(2):313-24. doi: 10.1007/s10741-011-9248-0. Review.

PMID:
21559880
3.

Early and personalized ambulatory follow-up to tailor furosemide and fluid intake according to congestion in post-discharge heart failure.

Parrinello G, Torres D, Paterna S, Di Pasquale P, Trapanese C, Cardillo M, Bellanca M, Fasullo S, Licata G.

Intern Emerg Med. 2013 Apr;8(3):221-8. doi: 10.1007/s11739-011-0602-y. Epub 2011 May 19.

PMID:
21594682
4.

Biventricular pacing (cardiac resynchronization therapy): an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2005;5(13):1-60. Epub 2005 Sep 1.

5.

Congestive heart failure and decongestion ability of two different treatments: continuous renal replacement and diuretic therapy: experience of a cardiac step down unit.

Giglioli C, Spini V, Landi D, Chiostri M, Romano SM, Calabretta R, Gensini GF, Cecchi E.

Acta Cardiol. 2013 Aug;68(4):355-64.

6.

Admission plasma neutrophil gelatinase associated lipocalin (NGAL) predicts worsening renal function during hospitalization and post discharge outcome in patients with acute heart failure.

Palazzuoli A, Ruocco G, Beltrami M, Franci B, Pellegrini M, Lucani B, Nuti R, Ronco C.

Acute Card Care. 2014 Sep;16(3):93-101. doi: 10.3109/17482941.2014.911915. Epub 2014 May 16.

PMID:
24836558
7.

Diagnosis and management of fluid overload in heart failure and cardio-renal syndrome: the "5B" approach.

Ronco C, Kaushik M, Valle R, Aspromonte N, Peacock WF 4th.

Semin Nephrol. 2012 Jan;32(1):129-41. doi: 10.1016/j.semnephrol.2011.11.016.

PMID:
22365171
8.

Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G; EVEREST Trial investigators.

Eur J Heart Fail. 2013 Dec;15(12):1401-11. doi: 10.1093/eurjhf/hft110. Epub 2013 Jul 11.

9.

Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations.

Brandimarte F, Vaduganathan M, Mureddu GF, Cacciatore G, Sabbah HN, Fonarow GC, Goldsmith SR, Butler J, Fedele F, Gheorghiade M.

Heart Fail Rev. 2013 Mar;18(2):167-76. doi: 10.1007/s10741-012-9317-z. Review.

PMID:
22572909
10.

Extracorporeal ultrafiltration for congestive heart failure patients.

Costanzo MR, Ronco C.

Contrib Nephrol. 2011;171:201-7. doi: 10.1159/000327152. Epub 2011 May 23.

PMID:
21625112
11.

Extracorporeal fluid removal in heart failure patients.

Costanzo MR, Agostoni P, Marenzi G.

Contrib Nephrol. 2010;164:173-98. doi: 10.1159/000313730. Epub 2010 Apr 20. Review.

PMID:
20428003
12.

Management and monitoring of haemodynamic complications in acute heart failure.

Aspromonte N, Cruz DN, Valle R, Ronco C.

Heart Fail Rev. 2011 Nov;16(6):575-81. doi: 10.1007/s10741-011-9229-3. Review.

PMID:
21301959
13.

Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure.

Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW.

Am Heart J. 2000 Dec;140(6):840-7.

PMID:
11099986
14.

Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).

O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy CW, Young JB, Fonarow GC.

Am Heart J. 2008 Oct;156(4):662-73. doi: 10.1016/j.ahj.2008.04.030.

PMID:
18926148
15.

Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin.

Palazzuoli A, Masson S, Ronco C, Maisel A.

Heart Fail Rev. 2014 Mar;19(2):267-84. doi: 10.1007/s10741-013-9391-x. Review.

PMID:
23563622
16.

Why, when, and how to assess pulmonary congestion in heart failure: pathophysiological, clinical, and methodological implications.

Picano E, Gargani L, Gheorghiade M.

Heart Fail Rev. 2010 Jan;15(1):63-72. doi: 10.1007/s10741-009-9148-8. Review.

PMID:
19504345
17.

Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.

Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, O'Connor CM, Yancy CW, Young J.

Am Heart J. 2004 Jul;148(1):43-51.

PMID:
15215791
18.
19.

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.

JAMA. 2004 Apr 28;291(16):1963-71.

PMID:
15113814
20.

Rationale and design of the Aquapheresis Versus Intravenous Diuretics and Hospitalization for Heart Failure (AVOID-HF) trial.

Costanzo MR, Negoianu D, Fonarow GC, Jaski BE, Bart BA, Heywood JT, Nabut JL, Schollmeyer MP.

Am Heart J. 2015 Sep;170(3):471-82. doi: 10.1016/j.ahj.2015.05.019. Epub 2015 Jun 14.

PMID:
26385030
Items per page

Supplemental Content

Write to the Help Desk